Financial Data and Key Metrics Changes - In Q4 2025, total net revenue was $34.1 million, including $26.4 million from MIPLYFFA sales, $400,000 from OLPRUVA, and $5.6 million from net reimbursements under the global EAP [22][23] - For the full year 2025, net revenue reached $106.5 million, with $87.4 million from MIPLYFFA sales, compared to a net loss of $105.5 million in 2024 [25] - Operating expenses for Q4 2025 were $23 million, a decrease of $1.5 million year-over-year, while R&D expenses decreased by $5.8 million to $2.6 million [22][24] Business Line Data and Key Metrics Changes - MIPLYFFA generated $87.4 million in revenue for the full year 2025, with a total of 161 enrollments since launch, including 52 in the first full year of commercialization [5][6][15] - The global expanded access program (EAP) had 113 patients enrolled by the end of 2025, with ongoing efforts to expand access beyond the U.S. [8][9] Market Data and Key Metrics Changes - In the U.S., the estimated prevalence of Niemann-Pick disease type C (NPC) is approximately 900 individuals, with 300-350 currently diagnosed [7][10] - In Europe, the estimated prevalence of NPC is around 1,100 individuals, with the current EAP supporting nearly 10% of this population [9] Company Strategy and Development Direction - The company aims to redefine therapies for rare diseases, focusing on patient-centricity and innovation [4] - A strategic move to Boston is intended to enhance collaboration and access to specialized talent within the biotech ecosystem [12] - The company is pursuing a patent term extension for MIPLYFFA, which could provide additional exclusivity [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MIPLYFFA, driven by strong clinical data and increased awareness among healthcare providers [15][16] - The company is optimistic about the continued identification of newly diagnosed patients and the overall market potential for MIPLYFFA [16][20] Other Important Information - The company has engaged the FDA regarding regulatory options to accelerate the development of celiprolol for vascular Ehlers-Danlos syndrome [12][70] - The company has a strong balance sheet with $238.9 million in cash and equivalents, allowing for independent operation and investment in growth opportunities [90] Q&A Session Summary Question: Can you provide details on the split of new diagnoses versus previously identified patients? - Management noted that there has been meaningful growth in newly diagnosed patients, attributed to clinical data strength and disease awareness campaigns [32][33] Question: What is the expected timeline for diagnosis confirmation? - The average time for test results is estimated to be about three weeks, facilitating quicker clinical decision-making [41] Question: Can you discuss persistency rates for patients on therapy? - Management indicated that it is too early to provide meaningful data on persistency but noted encouraging refill rates [46][47] Question: How is the initial experience with the Uniphar collaboration? - The company is pleased with the collaboration and expects continued growth in patient access through this partnership [48][49] Question: What is the total addressable market for diagnosed NPC patients? - Management believes they have engaged approximately 40%-50% of the diagnosed patients currently enrolled to receive MIPLYFFA [80]

As filed with the U.S. Securities and Exchange Commission on March 9, 2026. Registration No. 333-291575 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Breeze Acquisition Corp. II (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization ...

Summary of iBio Conference Call Company Overview - **Company**: iBio (NYSEAM:IBIO) - **Industry**: Biotechnology, specifically focusing on cardiometabolic diseases and obesity treatments Key Points and Arguments Long-term Vision - iBio pivoted into the cardiometabolic space two years ago, focusing on treatments that follow GLP-1s, which are becoming a cornerstone in obesity treatment. The company aims to address unmet needs in patient care within this space [7][8] Value Inflection Points - Upcoming milestones include: - External data from Wave and Arrowhead - Filing for Activin E by the end of the year, with potential interim data by the end of next year - Progress on bispecific myostatin activin A program, expected to enter the clinic in the second half of next year - Myostatin program acceptance in Australia, with first patient dosing anticipated in Q3 [12][12][12] IBIO-610 (Activin E Antibody) - The antibody targets the Activin E pathway at the protein level in blood, differentiating it from competitors focusing on gene-level interventions [25] - Aiming for near-complete inhibition of the pathway, which may lead to better efficacy compared to competitors [26] - Safety profile is expected to be favorable due to the extensive history of antibody use [29] - Designed for long-acting subcutaneous administration, with a half-life of approximately 100 days in humans [33] Competitive Landscape - iBio is learning from competitors' data on visceral fat and liver fat reductions, which may inform their trial designs and patient populations [35][36] - The company is particularly interested in inflammation biomarkers, which could link to cardiovascular disease protection [40][41] Regulatory Considerations - The company is cautious about regulatory pathways, emphasizing the need for endpoints that reflect real patient benefits rather than just weight loss [44][45] Patient Populations - Targeting a broad range of patients, including those with type 2 diabetes, liver fibrosis, and obstructive sleep apnea [51][52] - The potential for the drug to address weight maintenance in obesity is highlighted as a significant unmet need [49] Pipeline and Future Indications - iBio is developing a bispecific antibody targeting myostatin, GDF11, and activin A, which may address multi-organ diseases like heart failure with preserved ejection fraction [58][59] - The company is not focused on rare diseases but is open to partnerships for those indications [62] Financial Overview - iBio has cash reserves extending into Q1 2028, prioritizing the development of Activin E, bispecific, and myostatin programs [71] - Current market cap is approximately $350 million, with a fully diluted cap closer to $500 million [71] Partnership Strategy - iBio is considering partnerships for larger indications like obesity, while smaller indications may be developed independently [73] - The company is selective in partnerships, aiming to maximize shareholder value [74] Underappreciated Aspects - The team, platform, and persistence are highlighted as key strengths that differentiate iBio in the competitive landscape [77] Additional Important Content - The integration of AI in drug discovery is emphasized, allowing for the development of more effective and manufacturable antibodies [66][68] - The company is focused on optimizing both antibodies and antigens, which sets it apart from competitors [67][68]

Core Viewpoint - Relmada Therapeutics, Inc. is actively participating in the Leerink Partners Global Healthcare Conference, highlighting its commitment to advancing innovative therapies in oncology and central nervous system disorders [1]. Group 1: Conference Participation - The CEO Sergio Traversa and CFO Maged Shenouda will represent the company at the conference held in Miami, Florida from March 8-11, 2026 [1]. - A fireside chat is scheduled for March 10, 2026, at 8:40 AM ET, with a webcast available for interested parties [2]. - Management will also be available for one-on-one investor meetings during the conference, indicating an opportunity for direct engagement with investors [2]. Group 2: Company Overview - Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions [4]. - The company's lead candidates, NDV-01 and sepranolone, are progressing through mid-stage clinical development, aiming to address significant unmet medical needs [4].

Market Overview - The trading day experienced significant volatility, with the VIX index rising, indicating increased market uncertainty [2][3] - WTI crude oil saw a dramatic price swing of nearly $40 within the same day, marking a notable fluctuation reminiscent of early pandemic levels [5] Market Performance - The Dow Jones Industrial Average closed up approximately 0.5%, adding over 200 points, while the S&P 500 reversed from a decline of 1.5% to finish up 0.8% [6] - The Nasdaq composite increased by about 1.4%, and the Russell 2000 rose by 1.1% [6] Sector Performance - Technology was the strongest sector, gaining around 1.8%, followed by communication services, healthcare, and industrials [8] - Financials were the worst-performing sector, down about 0.5%, while energy also declined by approximately 0.4% [8] Notable Company Movements - Hims and Hers Health experienced a significant increase of nearly 41% after resolving litigation with Novo Nordisk regarding weight loss drugs [9][10] - Novo Nordisk's stock rose by about 3.1% amid competitive pressures in the GLP-1 market [10] - Capricorn Therapeutics, a clinical-stage biotech company, saw its stock rise nearly 10% due to expectations of a supportive regulatory environment from the FDA [11] - Region X Bio, another biotech firm, increased by about 20% on similar regulatory optimism [12] Legal and Regulatory Developments - Live Nation and its Ticketmaster subsidiary reached a settlement with federal antitrust authorities, resulting in a stock increase of approximately 6.2% [13] Declining Stocks - Boeing's stock fell by about 2.6% due to concerns over rising fuel costs affecting airline growth plans [15][16] - Uber and DoorDash stocks declined by approximately 1.7% and 1.4%, respectively, as rising fuel costs could impact consumer pricing [17][18] - Paramount's shares dropped by about 6.7% following Tencent's announcement of a significant investment [20]

Group 1 - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that drive valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced biotech investors [1] - The investing group provides insights such as catalysts to watch, buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-by-market analysis [1]

Core Insights - Voyager Therapeutics anticipates 2026 to be a transformative year, focusing on tau-targeting assets for Alzheimer's disease, novel I.V.-delivered neuro gene therapies, and the advancement of its nonviral delivery platform, Voyager NeuroShuttle [2][4] Financial Position - As of December 31, 2025, Voyager reported a cash position of $201.7 million, which is expected to sustain operations into 2028 [7][8] - Collaboration revenue for Q4 2025 was $15.3 million, up from $6.3 million in Q4 2024, while total collaboration revenue for the year was $40.4 million, down from $80.0 million in 2024 [12][20] Research and Development Highlights - The company expects to complete a GLP toxicology study for VY1706 in Q1 2026, with an IND application submission planned for Q2 2026 and first-in-human dosing anticipated in H2 2026 [5][6] - VY7523's clinical trial for Alzheimer's disease completed enrollment in Q4 2025, with tau PET imaging data expected in H2 2026 [6][12] Partnerships and Collaborations - Neurocrine plans to initiate a clinical trial with NBIB-'223 for Friedreich's ataxia in H2 2026, pending FDA IND clearance [6] - Voyager's partnership with Novartis for Huntington's disease and spinal muscular atrophy continues to advance [6] Pipeline Updates - Voyager has paused development of its apolipoprotein E gene therapy program to prioritize more advanced programs, despite demonstrating promising results in murine studies [5][6] - The Voyager NeuroShuttle platform has shown sustained brain exposure in a proof-of-concept study, indicating potential for high brain penetration with genetic medicines [5][6]

Core Viewpoint - Dianthus Therapeutics, Inc. has initiated a public offering of $400 million in common stock, with an additional option for underwriters to purchase up to $60 million more, aimed at advancing its clinical and preclinical development activities [1][2]. Group 1: Offering Details - The public offering consists of $400 million in shares of common stock or pre-funded warrants for certain investors [1]. - Underwriters will have a 30-day option to purchase an additional $60 million of shares at the public offering price [1]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes [2]. Group 3: Company Background - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [5].

Summary of Zymeworks Conference Call Company Overview - **Company**: Zymeworks (NasdaqGS: ZYME) - **Focus**: Specializes in antibody-drug conjugates (ADCs), T-cell engagers, and protein engineering - **Key Product**: Zanya, licensed to Jazz Pharmaceuticals, has shown positive results in phase 3 clinical trials for gastric cancer [5][6] Core Strategies and Financials - **R&D Focus**: Zymeworks is evolving to concentrate on research and development (R&D) and partnerships rather than commercialization of drugs [7][11] - **Capital Deployment**: The company has access to over $440 million in near-term milestones and high teen digit royalties from Jazz, which will be strategically deployed across three areas: internal pipeline, asset aggregation, and stock buybacks [12][15] - **Stock Buyback**: Authorized $120 million in stock buybacks, with $62 million already implemented [15] Clinical Developments - **Zanya's Clinical Success**: Positive progression-free survival (PFS) of around 12 months in gastric cancer, with safety data indicating low rates of discontinuation due to adverse effects [34][35] - **Future Approval**: Anticipated approval for Zanya in the U.S. in the latter half of 2026 [35] Partnerships and Licensing - **Royalty Pharma Deal**: Zymeworks entered a $250 million debt financing deal with Royalty Pharma, retaining 70% of royalties until the debt is repaid, allowing for low-cost capital access [21][46] - **Janssen Collaboration**: The KLK2 T-cell engager licensed to J&J is undergoing three registration trials, indicating strong interest and potential for future growth in prostate cancer treatment [57][58] Pipeline and Future Directions - **ADC Strategy**: Zymeworks has two ADC assets in clinical trials, focusing on unique antibody designs and payloads to enhance therapeutic windows [49][51] - **Upcoming Trials**: Plans to advance a DLL3-targeted T-cell engager and an IL-4/IL-33 combination for COPD and asthma into clinical trials by late 2026 [53][54] - **Preclinical Developments**: Ongoing work on a RAS ADC and other T-cell engagers, with data expected later this year [54] Market Position and Competitive Landscape - **Competitive Edge**: Zymeworks aims to differentiate itself by leveraging internal R&D capabilities to enhance the success of acquired assets, unlike traditional royalty companies [17][18] - **Market Expectations**: Anticipated that Zanya will replace existing treatments like Herceptin in gastric cancer, with ongoing evaluations in breast cancer trials showing promising early interest [36][40][44] Conclusion - Zymeworks is strategically positioned to leverage its successful clinical data and partnerships to enhance its pipeline and shareholder value, with a clear focus on R&D and innovative drug development strategies.

Industry Overview - J.P. Morgan highlights trends defining healthcare in 2026, particularly in the biopharma segment, which is gaining momentum and attracting investor interest [1] - Mergers and acquisitions in the biopharma sector are increasing as companies seek to bolster their pipelines ahead of patent expirations for major drugs [1] - Investors are optimistic about smaller biopharma companies with promising drugs and clear value paths, alongside a convergence of biotech and digital health [2] Investment Opportunities - There is an expectation of more deals in 2026 and key clinical results on the horizon, presenting opportunities for informed investors [2] - A methodology was employed to identify U.S.-listed biotechnology companies with market capitalizations above $2 billion, a short interest ratio greater than 15%, and at least 15% upside potential [5][6] Hedge Fund Interest - The focus on stocks that hedge funds are investing in is based on research indicating that mimicking top hedge fund picks can lead to market outperformance [7] - The article lists the 10 most shorted biotech stocks to buy according to hedge funds, indicating strong interest and potential for growth [3] Company Spotlight: CRISPR Therapeutics AG - CRISPR Therapeutics AG is identified as one of the most shorted biotech stocks to buy, with significant attention from hedge funds [8] - Morgan Stanley raised its price target for CRISPR Therapeutics AG from $32 to $33 while maintaining an Underweight rating, reflecting updated estimates and pipeline evaluations [9] - Needham increased its price target for CRISPR Therapeutics AG from $80 to $82, maintaining a Buy rating with over 45% upside potential [10] - The company reported that its therapy Casgevy generated $116 million in sales in 2025, exceeding expectations and indicating strong commercial traction [11] - CRISPR Therapeutics AG focuses on gene editing to develop potentially curative medicines for serious diseases, positioning itself as a leader in genetic medicine [12]